Effective January 31, 2019, if an Original Medicare order requires an Advance Beneficiary Notice (ABN) but does not include one, the order will be placed on hold. Not all Original Medicare orders will require an ABN - learn more about when one may be required here.
- Cancer Type
- Sample Type
- Results Expected
What is FoundationOne Liquid?
FoundationOne Liquid helps guide cancer care from a simple blood draw.
This liquid biopsy test provides targeted gene and microsatellite instability (MSI) results1 that can help direct therapy selection and clinical trial options for advanced-stage cancer patients using a minimally invasive sample type. By analyzing ctDNA with our comprehensive genomic profiling approach and providing expertly curated reports, FoundationOne Liquid empowers providers to make more informed clinical decisions even when tissue is not ideal.
- A single liquid biopsy test that detects the 4 main classes of genomic alterations
- Provides a comprehensive genomic profile including resistance mutations or fusions in lung cancer4
- Now also includes MSI status and an expanded gene list including homologous recombination deficiency (HRD) genes to help guide therapy selection and clinical trials
- Requires only two 8.5mL tubes of blood
Please see footnotes below for information on PPV and sensitivity